血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂对ICU脓毒症相关性脑病患者的影响OA
Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on ICU Patients with Sepsis-Associated Encephalopathy
目的 探讨在ICU收治的脓毒症相关性脑病(sepsis-associated encephalopathy,SAE)患者中,血管紧张素转换酶抑制剂(angiotensin-converting enzyme inhibitor,ACEI)及血管紧张素受体阻滞剂(angiotensin receptor blocker,ARB)的使用与全因死亡率之间的关联.方法 本研究为一项回顾性队列研究,数据来源于MIMIC-IV数据库.筛选确诊为SAE的患者,并将其分为用药组(暴露组)与未用药组(对照组).采用倾向评分匹配(propensity score matching,PSM)平衡两组基线特征,采用Kaplan-Meier生存分析及Cox比例风险模型评估ACEI/ARB对患者死亡率的影响,并进一步通过亚组分析评估不同人群中药效的异质性.结果 共纳入11 613例SAE患者,其中3 893例接受ACEI/ARB治疗.经PSM后,两组各纳入3 256例患者,多数基线指标趋于平衡.在匹配后队列中,多变量Cox比例风险回归模型(进一步校正了PSM后仍存在差异的混杂因素)分析显示,使用ACEI/ARB是与降低全因死亡风险独立相关的保护因素,风险比(HR)=0.39,95%CI:0.35-0.43,(P<0.001).敏感性分析得出一致结论(HR=0.37~0.38).Kaplan-Meier生存曲线显示,在所有观察时间点,暴露组患者的累积生存率均显著高于非暴露组(P<0.001).亚组分析提示,种族、是否接受连续性肾脏替代治疗(CRRT)以及是否合并高血压,与ACEI/ARB的疗效存在显著交互作用(P<0.05).结论 在ICU住院的SAE患者中,应用ACEI/ARB可能与短期及长期死亡风险下降相关,尤其在接受CRRT治疗或未合并高血压的患者中获益更为显著.本研究结果为相关临床实践提供了参考,但其结论仍需更多前瞻性研究进一步验证.
Objective To investigate the association between the use of angiotensin-converting enzyme inhibitors(ACEIs)and angiotensin receptor blockers(ARBs)and all-cause mortality in patients with sepsis-associated encephalopathy(SAE)admitted to the intensive care unit(ICU).Methods This is a retrospective cohort study that identified patients with SAE from the Medical Informa-tion Mart for Intensive Care(MIMIC)database in this analysis and grouped them into the ACEI/ARB and non-ACEI/ARB groups.The baseline characteristics were balanced through propensity score matching(PSM).The association between ACEI/ARB therapy and mor-tality was assessed using Kaplan-Meier analysis and Cox proportional hazards models.Subgroup analysis was applied to investigate potential differences in the effects of drug therapy on clinical outcomes across various groups.Results Among the final participants with SAE admitted to ICU,33.6%received ACEI/ARB,while 66.4%did not.After PSM,we had 3,256 individuals in each group,most baseline characteristics were balanced.In the matched cohort,the multivariable Cox proportional hazards regression model(which further adjusted for residual confounding factors that remained unbalanced after PSM)showed that ACEI/ARB use was indepen-dently associated with a reduced risk of all-cause mortality,with a hazard ratio(HR)of 0.39(95%confidence interval(CI):0.35-0.43,P<0.001).Sensitivity analysis yielded consistent results(HR=0.37~0.38).Kaplan-Meier survival curves demonstrated that the cumulative survival rate was significantly higher in the exposed group than in the non-exposed group at all observed time points(Log-rank P<0.001).Additionally,subsequent subgroup analysis further showed that race,receiving CRRT,and having hypertension have a significant interaction with ACEI/ARB efficacy.Conclusions ACEI/ARB medications in SAE patients during hospitalization may decrease all-cause mortality.The benefit was more pronounced in patients receiving CRRT than in those not receiving CRRT.More-over,compared with patients with hypertension,the benefit in reducing mortality was greater in patients without hypertension.How-ever,more high-quality research is needed for verification.
高伟燕;魏榛;陈伟;雷迁
西南医科大学附属医院 麻醉科(泸州 646000)||四川省医学科学院·四川省人民医院(电子科技大学附属医院)麻醉手术中心(成都 610000)四川省医学科学院·四川省人民医院(电子科技大学附属医院)麻醉手术中心(成都 610000)四川省医学科学院·四川省人民医院(电子科技大学附属医院)麻醉手术中心(成都 610000)西南医科大学附属医院 麻醉科(泸州 646000)||四川省医学科学院·四川省人民医院(电子科技大学附属医院)麻醉手术中心(成都 610000)
医药卫生
脓毒症相关性脑病MIMIC数据库血管紧张素转换酶抑制剂血管紧张素受体阻滞剂死亡率
Sepsis-associated encephalopathy(SAE)MIMIC databaseAngiotensin-converting enzyme inhibitorAngioten-sin receptor blockerMortality
《西南医科大学学报》 2026 (5)
623-630,8
国家自然科学基金(82470290)
评论